Form 4: Arcutis EVP & CMO Sells Shares Post-Option Exercise

Patrick Burnett, Arcutis Biotherapeutics' EVP and Chief Medical Officer, executed a pre-planned sale of 17,250 common shares after exercising stock options, realizing a significant gain.

Summary

• Patrick Burnett, Executive Vice President and Chief Medical Officer of Arcutis Biotherapeutics, Inc. (ARQT), reported transactions on November 6, 2025.
• Burnett exercised stock options to acquire 17,250 shares of common stock at an exercise price of $3.64 per share.
• Immediately following the exercise, Burnett sold all 17,250 shares of common stock at a weighted average price of $24.1823 per share.
• The sales occurred in multiple transactions with prices ranging from $23.79 to $24.4493.
• These transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024, with a plan end date of February 27, 2026.
• Following these transactions, Burnett beneficially owns 98,325 shares of common stock directly and 155,250 derivative securities (stock options).

Sentiment

Score: 5

Explanation: The filing reports a routine insider transaction under a pre-arranged plan. While the insider realized a significant profit, which is positive for the individual, it is neutral for the company's operational outlook. The sale of shares, even planned, can sometimes be viewed with slight caution by investors, but the context of a 10b5-1 plan mitigates negative sentiment.

Positives

• The reporting person realized a substantial profit from exercising options at $3.64 and selling shares at an average of $24.1823.
• The transactions were executed under a pre-arranged 10b5-1 trading plan, indicating a structured approach to insider stock sales rather than an immediate reaction to new information.

Negatives

• Insider selling, even under a 10b5-1 plan, can sometimes be perceived negatively by investors, suggesting a lack of confidence, although this is a common practice for executive compensation.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction. It solely reports an insider's stock transactions.

Industry Context

This filing reports a routine insider transaction for an executive in the biotechnology sector. Such transactions, particularly when executed under a 10b5-1 plan, are common for executive compensation and personal financial planning and do not inherently reflect specific industry trends or competitive positioning.

Comparison to Industry Standards

• Insider transactions like option exercises and subsequent sales are standard practices for executives across various industries, including biotechnology.
• The use of a 10b5-1 trading plan aligns with best practices for managing insider stock sales, providing an affirmative defense against claims of trading on material non-public information.
• No specific comparable companies or projects are relevant for this type of transactional filing.

Corporate Governance

Stakeholder Impact

• Shareholders: Minor dilution from the option exercise (though offset by the sale), and potential for varied interpretations regarding insider selling, even under a 10b5-1 plan.
• Employees: No direct impact mentioned, but executive compensation practices can influence overall employee morale and perception of leadership.

Next Steps

• The 10b5-1 trading plan is scheduled to end on February 27, 2026.
• The remaining stock options will continue to vest monthly until January 12, 2028, subject to continued service.

Key Dates

Keywords

Arcutis Biotherapeutics, ARQT, Insider Trading, Form 4, Stock Options, Executive Compensation, 10b5-1 Plan, Patrick Burnett, Biotechnology